DSM and Phynova to Distribute Reducose® Globally

distribution,dsm,natural,diabetes,blood glucose,ingredient

12 March 2019 - DSM and Phynova have signed a global distribution and collaboration agreement for Reducose®, a patented, natural ingredient for healthy blood glucose levels. Reducose® is backed by several clinical studies and it has regulatory approvals in multiple regions across the world.

Phynova CEO, Mr Robert Miller says: “We are delighted to work with DSM, the leading global health and nutrition ingredient specialist. Along with the distribution and sales of Reducose® we will collaborate closely with them on product development, clinical research, regulatory approvals and marketing.”

Ivo Lansbergen, VP Global Strategic Marketing, DSM Human Nutrition and Health says: “Phynova is a strategic partner for DSM to provide the right nutritional solutions to address the ever-growing health concerns linked to maintaining healthy blood glucose. The combined strengths of DSM and Phynova provide an excellent platform for addressing this major societal challenge.”

Reducose® is a water extract of white mulberry leaves (Morus alba), a plant that has been used for centuries around the world as a food and animal feed. Reducose® can be added in small quantities to foods and drinks or taken as a small supplement. It reduces the impact of high-glycaemic sugars, as well as other carbohydrates, on the body. It does this by reducing the absorption of sugars and other carbohydrates by up to 40%. Reducose® is patent protected and has undergone rigorous safety and efficacy testing.

Diabetes is a rapidly growing health issue with an estimated 425 million adults affected globally. The incidence of prediabetes is even higher with an estimated 390 million prediabetic adults in China alone. Two trends are converging with these increasing numbers and the related healthcare costs: governments are actively working to increase consumer awareness about healthy nutrition and reduction of high-glycaemic foods, and secondly, there is a new generation of non-invasive wearable devices coming to the market that will be able to continuously monitor and make people aware of their blood glucose status.